复星医药(02196.HK)弹逾7%重越50天线 投资癌症药上市申请获受理
复星医药(02196.HK)表示其投资的治疗癌症药上市申请获受理,该股今早扭两连跌,股价一举重越20天、10天、100天及50天线(22.3-22.85元),最高见23.3元,暂受制牛熊线(23.9元),现造23.2元,回升7.2%,成交增至372万股;其A股涨5.3%报28.19元人民币。
复星医药公布,其投资合营复星凯特近日收到国家药监局药品上市注册审评受理通告,已正式受理公司的益基利仑赛注射液(即抗人CD19 CAR-T细胞注射液)上市注册。该产品主要用於覆发难治性成人大B细胞淋巴瘤的治疗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.